Step 1
HIV Env Recognition
An HIV-targeting arm, such as broadly neutralizing Env recognition logic, supports binding to HIV-associated infected-cell targets.
HIV Trispecific Antibody
A trispecific antibody strategy designed to combine HIV-associated target recognition with immune engagement and co-stimulatory logic for infected-cell clearance.
HIV-associated target recognition, immune engagement, and co-stimulatory logic.
Macro HRD's trispecific antibody work is positioned around HIV reservoir-directed clearance rather than a generic multi-target antibody platform. The conceptual architecture combines HIV Env-binding or bNAb logic with CD3 engagement and CD28 co-stimulation.
Single molecule, HIV-relevant recognition and immune-engagement domains.
A trispecific antibody is an engineered molecule containing coordinated functional binding domains. In the HIV program, those roles are framed as HIV-associated target recognition, CD3 immune engagement, and CD28 co-stimulatory support.
The result is a single molecule designed to identify HIV-associated infected-cell targets and recruit immune effectors with target-dependent immune activation.
Env recognition, CD3 engagement, and CD28 co-stimulation.
The HIV antibody strategy works by combining target recognition, immune engagement, and co-stimulatory support in one molecule. Current claims are presented as research-stage and aligned with available program evidence.
Step 2
CD3 Engagement
CD3 engagement may redirect T cells toward infected-cell clearance where target engagement is achieved.
Step 3
CD28 Co-Stimulation
CD28 co-stimulatory logic may support immune activation and effector function.
Step 4
Reservoir-Directed Clearance
The construct is designed to support immune-mediated infected-cell clearance.
HIV Env-binding logic, CD3 engagement, and CD28 co-stimulation.
The conceptual program architecture is described around an HIV Env-binding arm or broadly neutralizing antibody logic, CD3 immune engagement, and CD28 co-stimulation. Published trispecific and bNAb literature supports the scientific rationale, while Macro HRD-owned development progress is presented separately according to disclosed program evidence.
Conceptual Arm 01
HIV Env-binding arm
Broadly neutralizing antibody logic may support recognition of HIV-associated infected-cell targets.
Conceptual Arms 02-03
CD3 x CD28 logic
CD3 engagement and CD28 co-stimulation may support target-dependent immune activation and infected-cell clearance.
Research-stage capabilities for reservoir-directed HIV antibody development.
The antibody strategy is designed for target recognition, T cell engagement, co-stimulatory support, and programmable architecture.
01 Capability
Trispecific Architecture
Single molecule with HIV-associated target recognition, CD3 engagement, and CD28 co-stimulatory support.
02 Capability
Infected-Cell Targeting
HIV-associated infected-cell targets can be recognized for immune engagement where target binding is achieved.
03 Capability
Immune Engagement
The strategy may recruit T-cell effector mechanisms to infected-cell targets through CD3 engagement.
04 Capability
Co-Stimulatory Support
CD28 logic may support immune activation and effector function in a target-dependent context.
05 Capability
Programmable Architecture
A trispecific backbone can be re-armed with different binding domains for different targets.
06 Capability
HIV Trispecific Antibody Fit
The architecture fits settings where viral variation, reservoir persistence, and coordinated immune engagement matter.
Evidence context for HIV antibody development.
Program evidence is organized to distinguish Macro HRD-owned development progress from background literature and collaborator context.
Construct-screening context
Construct screening is part of development and optimization, with public details aligned to approved disclosure.
Potency evaluation context
Potency-related information is presented with construct and assay details communicated through approved disclosure.
Affinity evaluation context
Affinity-related information for HIV-associated and immune-engagement binding is communicated through approved public disclosure.
Safety-margin context
Safety-margin information supports ongoing development evaluation.
Biologics confirmation
Biologics, CMC, and third-party validation context are communicated through approved public disclosure.
Clinical disclosure context
Clinical-context statements are communicated only through approved public disclosure.
Background literature
Published trispecific, bNAb, SHIV, and reservoir biology literature supports scientific rationale and is presented as background alongside Macro HRD-owned program status.
Research-stage disclosure
Program stages reflect current public progress, with future updates aligned to validated development evidence.
HIV reservoir-directed antibody application.
The primary application is HIV, where Env recognition, CD3 engagement, and CD28 co-stimulatory logic are evaluated for infected-cell clearance and reservoir-directed strategy support.
HIV Reservoir-Directed Strategy
In HIV, trispecific antibody architecture is used to support infected-cell recognition, immune engagement, and reservoir-directed clearance strategy development.
Future Infectious Disease Targets
Future use outside HIV is presented as exploratory until disease-specific target logic and validation data are available.
Connected to HIV program logic and optional formulation support.
The antibody strategy connects directly to HIV Trispecific Antibody (MACR - 001). Advanced LNP Blood–Brain Barrier Crossing Lipid Nanoparticle Delivery Platform and GEDM3DQ may support formulation evaluation or development planning where appropriate; AH-D remains a separate enveloped-virus peptide approach.